Showing posts with label Vaccine. Show all posts
Showing posts with label Vaccine. Show all posts

Saturday, 19 May 2012

Breast Cancer In Women-Anderson Cancer Center-Breast Cancer Vaccine-Houston Chronicle

New M.D. Anderson breast cancer vaccine shows promise

Researchers at Houston-based M.D. Anderson Cancer Center reported promising results from an experimental new breast cancer vaccine.The vaccine, one of many now in testing, significantly decreased the recurrence rate of breast cancer in women who had been treated for a common tumor type, according to a study led by The University of Texas M.D. Anderson Cancer Center, the Houston Chronicle reports.The new vaccine triggers the patient's immunity against a tumor protein, known as HER2, present to... (Source: bizjournals.com Health Care:Pharmaceuticals headlines) read more..

Tuesday, 10 April 2012

Immune Responses-Clinical Trial-Flu Shot-Vaccine

iBio shares jump with flu shot clinical trial

iBio's ($IBIO) shares have jumped 21% with the announcement that it has completed the first Phase I clinical trial of its plant-based vaccine for H1N1 influenza, HAC1. The study of the vaccine, produced by iBio's partner the Fraunhofer USA Center for Molecular Biotechnology, aimed to assess the vaccine's safety, as well as looking for early clues to its ability to trigger an immune response against the flu virus.The study showed that the vaccine was safe and well-tolerated at low and high doses, regardless of whether an adjuvant was used. The vaccine also triggered immune responses, with the best immune response seen in the people who received the highest dose of the vaccine without an adjuvant. This was a similar response to a marketed flu shot.The vaccine's development is supported by funding from the Defense Advanced Research Projects Agency (DARPA). The vaccine is based on iBio's iBioLaunch platform, which uses plants to produce engineered proteins. The researchers are analyzing the data and are preparing a manuscript for a peer-reviewed journal.- read the releaseRelated Articles:
H1N1 provides new universal flu vax hope
Plant-based H1N1 vax starts clinical trial
WHO says H1N1 pandemic has run its course
Up to 70M doses of unused H1N1 vax to be destroyed read more..

Tuesday, 3 April 2012

Immune Response-Breast Cancer-Vaccine-History-Women

Early Study Hints That Breast Cancer Vaccine Might Work

MONDAY, April 2 -- A vaccine to prevent breast cancer's return in women with a history of the disease has triggered the desired immune response in early research.The vaccine under development is aimed at preventing recurrence in women who have a... read more..


U.S. Women Could Be More Obese Than Believed

MONDAY, April 2 -- The way that obesity is currently measured greatly underestimates the actual number of women who are obese, a new study suggests.Almost half of women currently labeled as not obese by virtue of their body mass index (BMI) turned... read more..

Sunday, 1 April 2012

Chlamydia Trachomatis-Chlamydial Infection-Bacterial Infection-Chlamydia Vaccine

Genetic tweaking could create chlamydia vaccine

Sexually transmitted chlamydial infection is silent but insidious--there can be just a few mild symptoms but the damage is irreversible, leaving some women infertile or with long-term pain. There is currently no vaccine, but an Indiana University researcher has been given $2.3 million to try to create one.The award, from the National Institutes of Health, will support David E. Nelson and his team to genetically modify variants of Chlamydia trachomatis, which is also the leading cause of infectious blindness (trachoma) worldwide. This tweaking of the genome will help researchers understand why the bacteria is specific to certain tissues and hosts, and how it manages to hide from the immune system. This knowledge, it is hoped, will lead to a vaccine."In the long term we hope our work provides clues toward designing a vaccine and developing strong models of human chlamydial disease," Nelson said. "But most immediately we're looking to identify and characterize the factors that allow this pathogen to grow, how it interacts with other bacteria and how it avoids host immune systems so well."Chlamydia is the most commonly reported bacterial infection in the United States, with more than 1.3 million people infected in 2010. The infection can be treated easily with antibiotics. However, either because the infection can be silent, or because it's sexually transmitted, not everyone comes forward for treatment. Until a vaccine is available, abstaining from sex or using condoms is the only surefire way to be safe.- read the press releaseRelated Articles:
TX institutions partner with Merck on chlamydia vax
New chlamydia vaccine being tested read more..